CTC Detection Using Immunofluorescent Markers and Morphology
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and quantifying circulating tumor cells (CTCs) and circulating endothelial cells (CECs) face challenges due to their low abundance and heterogeneity, leading to inaccurate detection and classification.
Innovation Solution
A method that distinguishes CTCs from CTC mimics by determining the presence or absence of specific immunofluorescent markers and assessing morphology in non-enriched blood samples, allowing for accurate identification and quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunomagnetic bead-based capture is used to enrich rare cells, then sensitivity of detection is improved, but specificity deteriorates due to inability to distinguish CTCs from CTC mimics
Solution Approach 1:
The patent divides the detection process into multiple sequential steps: initial enrichment using immunomagnetic beads targeting EpCAM, followed by secondary classification using additional markers (CD45, CD31, cytokeratins) and morphological assessment. This segmentation allows the method to maintain the sensitivity benefits of enrichment while adding specificity through progressive filtering of CTC mimics
Solution Approach 2:
The patent introduces intermediate classification markers (CD45 for white blood cells, CD31 for endothelial cells) that act as mediators to distinguish CTC mimics from true CTCs. These intermediary markers bridge the gap between initial enrichment and final identification, enabling differentiation without compromising the sensitivity of the initial capture step
2Ease of operation
If single biomarker targeting is used for cell enrichment, then assay simplicity is improved, but classification accuracy deteriorates due to heterogeneity of CTC populations
Solution Approach 1:
The patent employs a multi-functional detection approach where different markers serve multiple purposes: EpCAM for initial enrichment, CD45 for identifying and excluding white blood cell mimics, CD31 for identifying and excluding endothelial cell mimics, and cytokeratins for confirming epithelial origin. This universal application of multiple markers across different cell type classifications maintains assay simplicity while dramatically improving classification accuracy
Solution Approach 2:
The patent changes the detection parameters from a single biomarker to a panel of biomarkers with different specificities. By adjusting the combination and sequence of marker detection (EpCAM → CD45/CD31 → cytokeratins), the method adapts to different cell populations and mimics, improving classification accuracy without significantly complicating the overall assay procedure
3Ease of operation
If flow cytometry is used for cell sorting, then cell separation capability is improved, but enumeration accuracy of rare cell populations deteriorates
Solution Approach 1:
The patent extracts the enumeration function from the sorting function by using immunomagnetic beads for enrichment followed by manual or automated microscopy for counting. This separation allows the enrichment step to optimize for capturing rare cells while the counting step optimizes for accurate enumeration, avoiding the limitations of flow cytometry where both functions are combined and compromise overall performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method improves the accuracy and specificity of CTC detection and quantification by distinguishing CTC mimics, reducing false positives, and enabling the characterization of CTC mimics as diagnostic and prognostic indicators.
Implementation Method 1
determining the presence or absence of one or more immunofluorescent CTC markers in nucleated cells in a non-enriched blood sample to detect a CTC candidate
Data Source
AI summary
The disclosure provides methods for detecting circulating endothelial cells (CECs) that mimic CTCs with respect to aspects of their immunofluorescent staining and with respect to aspects of their morphological characteristics (CTC mimics). The present disclosure is based, in part, on the unexpected discovery that CTC mimics can be detected in non-enriched blood samples among CTC candidate cells. The present disclosure is further based, in part, on the discovery that CTC mimics can be detected in non-enriched blood samples by combining the detection of one or more immunofluorescent markers in the nucleated cells of a non-enriched blood sample with an assessment of the morphology of the nucleated cells.